Cellceutix has developed three lead drug candidates—each with first-in-class potential across multiple clinical indications attributable to novel mechanisms of action—with dermatology, oncology, anti-inflammatory and antibiotic applications.
- Prurisol—an orally-delivered medicine for treating psoriasis
- Kevetrin—a non-genotoxic cancer drug that modulates p53
- Brilacidin—an immunomodulatory agent with anti-inflammatory/antibiotic properties
Based on sound science, and covered by strong intellectual property and patent protections, these drug candidates are in mid-to-late stage clinical trials.
Advancing under a number of special FDA designations to help expedite development, improve likelihood of drug approval and gain market exclusivity, they address large areas of unmet medical need and represent sizable commercial opportunities.
Click here for a Corporate Overview.